Related coverage linked through entity extraction aliases.
Apr 19, 2026
Healthcare stocks were described as a defensive sector facing 2026 reimbursement headwinds, while capex rankings showed HCA Healthcare, Johnson & Johnson and Merck at the top. The sources also highlighted how capex differs across providers, device makers and drug developers.
Apr 01, 2026
The FDA has approved Eli Lilly's GLP-1 weight loss pill Foundayo, which will compete with Novo Nordisk's Wegovy pill. Foundayo will be available through LillyDirect and pharmacies, with prices ranging from $25 with insurance to $149-$349 for cash payers. The approval sets up a new battle in the oral GLP-1 market between the two pharmaceutical giants.
Mar 26, 2026
The European Union has approved a higher 7.2 mg maintenance dose for Wegovy (semaglutide) for chronic weight management. Clinical trial data shows mean weight loss of 20-21% with the 7.2 mg dose compared to 17-18% with the standard 2.4 mg dose. The approval provides clinicians with an on-label option for patients with inadequate response to standard dosing.
Mar 25, 2026
NICE has upheld appeals to review its guidance on Alzheimer's drugs lecanemab and donanemab, sending the decision back to committee. The manufacturers argued NICE failed to account for the treatments' wider impact on unpaid carers. This comes amid broader challenges in neurodegenerative disease research following recent high-profile clinical trial failures.
Mar 23, 2026
MSN Laboratories has received CDSCO approval for generic semaglutide, targeting a commercial launch by March 2026. The GLP-1 receptor agonist is used for type-2 diabetes management and will expand access to advanced metabolic therapies in India. The approval comes amid regulatory momentum and patent expirations driving generic entry into the market.
Mar 17, 2026
New research shows patients on GLP-1 drugs may need to delay endoscopy procedures due to retained gastric contents, while a Cleveland Clinic study found 45% of obesity patients maintained weight loss one year after stopping the medications.
Mar 17, 2026
ACT Capital Management invested $7.25 million in Viking Therapeutics as the company advances its obesity drug candidate VK2735 into Phase 3 trials. India's drug regulator warned pharmaceutical companies against direct or surrogate advertising of weight-loss medicines, while South Korean drugmakers target year-end commercialization of domestically developed obesity treatments.
Mar 17, 2026
New NICE guidance recommends offering SGLT-2 inhibitors earlier in type 2 diabetes treatment, potentially preventing 17,000 deaths over three years while saving the NHS £560 million through generic medicines.
Mar 16, 2026
Eli Lilly announced positive Phase 3 results for EBGLYSS in pediatric atopic dermatitis, orforglipron in diabetes showing superiority over Rybelsus, and Retevmo in early-stage lung cancer, expanding potential indications across its portfolio.
Mar 14, 2026
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
Mar 14, 2026
Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.
Mar 13, 2026
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
Mar 11, 2026
Ascletis Pharma announced positive Phase II results for subcutaneous ASC30 showing 6.3% placebo-adjusted weight loss at 12 weeks, while advancing oral amylin receptor agonist ASC36 toward US FDA IND submission for obesity treatment.
Mar 10, 2026
Natco Pharma has received CDSCO approval to manufacture and market generic semaglutide injection in India, with a planned March 2026 launch. Eris Lifesciences will commercialize the product through a partnership.
Mar 09, 2026
Veru Inc. has enrolled the first patient in its Phase 2b PLATEAU clinical trial evaluating enobosarm combined with semaglutide for weight loss in older patients with obesity. The study will assess enobosarm's ability to preserve lean mass and physical function while augmenting fat loss.
Mar 08, 2026
Orforglipron, an oral GLP-1 receptor agonist, demonstrated greater reductions in HbA1c and body weight compared to oral semaglutide in adults with type 2 diabetes, with more patients achieving strict glycemic targets at one year.
Mar 06, 2026
New research links GLP-1 drugs like Ozempic to increased scurvy risk through appetite suppression and poor nutrition. University of Florida researchers are testing a GLP-1 implant for obese cats as feline obesity affects nearly 60% of US cats.
Mar 05, 2026
Semaglutide reduced osteoarthritis progression in obese mice through metabolic reprogramming of cartilage cells, independent of weight loss effects, according to research published in Cell Metabolism.
Mar 05, 2026
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
Feb 27, 2026
Abbott India will commercialize semaglutide, the diabetes drug behind Ozempic, under the brand name Extensior in India following a partnership with Novo Nordisk. The launch targets India's growing diabetes population of over 100 million people.
